

2013

- **Management and Accounting for Intellectual Capital**

“Valuation Implications of Pharmaceutical Companies R&D Regulatory Approval Notification”, by P. Hamill, P. McIlkenny, and K. Opong, *British Accounting Review*, 2013, 45(2): 99-111.

- **Governance , transparency and disclosure**

“What Makes Better Boards? A Closer Look at Diversity and Ownership”, by W. Ben-Amar, C. Francoeur, T. Hafsi, and R. Labelle, *British Journal of Management*, 2013, 24: 85-101.

“A comparative analysis of the effect of board characteristics and governance indices on companies’ costs of financing: The Canadian evidence”, by R. Gouiaa and D. Zéghal, *Corporate Ownership and Control*, 2013, 11(1): 136-151.

- **Enterprise Risk Management**

“The disclosure of enterprise risk management (ERM) information: an overview of Canadian regulations for risk disclosure”, by M. Maingot, T. Quon, and D. Zéghal, *Journal of Governance and Regulation*, 2013, 2(4):13-21.

- **International Financial Reporting Standards (IFRS)**

“IFRS Adoption in Canada: An Empirical Analysis of the Impact on Financial Statements”, by M. Blanchette, F.-É. Racicot, and K. Sedzro, *Research Report*, Editor: CGA Canada, 2013, 1-68.

- **Finance**

“The procyclicality of hedge fund alpha and beta”, by F.É. Racicot, and R. Théoret, *Journal of Derivatives & Hedge Funds* , 2013, 19(2): 109–128.